Immunology of gut mucosal vaccines

Immunological Reviews

Volumn 239, Issue 1, 2011, Pages 125-148

  Pasetti, Marcela F ^a   Simon, Jakub K ^a,b   Sztein, Marcelo B ^a,b   Levine, Myron M ^a,b  

^a Center for Vaccine Development   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Infectious diseases; Mucosa; Vaccination

Indexed keywords

ANTHRAX VACCINE; CHOLERA VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIVE VACCINE; MUTACOL; POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; SHANCHOL; SHIGELLA VACCINE; TY21A VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHOLERA; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; HELICOBACTER PYLORI; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INTESTINE EPITHELIUM; INTESTINE SECRETION; NONHUMAN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; ROTAVIRUS INFECTION; SALMONELLA TYPHI; SHIGELLA; TYPHOID FEVER; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ENTEROBACTERIACEAE INFECTIONS; GASTROINTESTINAL TRACT; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; INTESTINAL MUCOSA; POLIOVIRUS VACCINE, ORAL; ROTAVIRUS VACCINES; VACCINES; VACCINES, ATTENUATED;

EID: 78650541367     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2010.00970.x     Document Type: Article

References (248)

1. Plotkin SA. Vaccines: the fourth century. Clin Vaccine Immunol 2009;16:1709-1719.
2. Ruiz-Palacios GM, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11-22.
3. Germanier R, Fuer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis 1975;131:553-558.
4. Clemens JD, et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 1990;335:270-273.
5. Vesikari T, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354:23-33.
6. Levine MM, et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet 1988;2:467-470.
7. Madhi SA, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010;362:289-298.
8. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991;13:926-939.
9. Zaman K, Sack DA, Yunus M, et al. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine 2009;27:1333-1339.
10. Armah GE, et al. Efficacy of pentavalent human-bovine reassortant rotavirus vaccine against severe rotavirus gastroenteritis in sub-Saharan Africa: a randomized, double-blind, placebo-controlled trial. Lancet 2010;376:606-614.
11. Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol 2007;5:540-553.
12. Soloff AC, Barratt-Boyes SM. Enemy at the gates: dendritic cells and immunity to mucosal pathogens. Cell Res 2010;20:872-885.
13. Johansson-Lindbom B, Agace WW. Generation of gut-homing T cells and their localization to the small intestinal mucosa. Immunol Rev 2007;215:226-242.
14. Siewert C, et al. Induction of organ-selective CD4+ regulatory T cell homing. Eur J Immunol 2007;37:978-989.
15. Mora JR, et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science 2006;314:1157-1160.
16. Cerutti A. Location, location, location: B-cell differentiation in the gut lamina propria. Mucosal Immunol 2008;1:8-10.
17. Macpherson AJ, Gatto D, Sainsbury E, Harriman GR, Hengartner H, Zinkernagel RM. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science 2000;288:2222-2226.
18. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2007;25:5467-5484.
19. Kett K, Brandtzaeg P, Radl J, Haaijman JJ. Different subclass distribution of IgA-producing cells in human lymphoid organs and various secretory tissues. J Immunol 1986;136:3631-3635.
20. Macpherson AJ, McCoy KD, Johansen FE, Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunol 2008;1:11-22.
21. Hutchings AB, et al. Secretory immunoglobulin A antibodies against the sigma1 outer capsid protein of reovirus type 1 Lang prevent infection of mouse Peyer's patches. J Virol 2004;78:947-957.
22. Schwartz-Cornil I, Benureau Y, Greenberg H, Hendrickson BA, Cohen J. Heterologous protection induced by the inner capsid proteins of rotavirus requires transcytosis of mucosal immunoglobulins. J Virol 2002;76:8110-8117.
23. Mazanec MB, Kaetzel CS, Lamm ME, Fletcher D, Nedrud JG. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci USA 1992;89:6901-6905.
24. Mazanec MB, Nedrud JG, Kaetzel CS, Lamm ME. A three-tiered view of the role of IgA in mucosal defense. Immunol Today 1993;14:430-435.
25. Boullier S, et al. Secretory IgA-mediated neutralization of Shigella flexneri prevents intestinal tissue destruction by down-regulating inflammatory circuits. J Immunol 2009;183:5879-5885.
26. Israel EJ, et al. Expression of the neonatal Fc receptor, FcRn, on human intestinal epithelial cells. Immunology 1997;92:69-74.
27. Dickinson BL, et al. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest 1999;104:903-911.
28. Yoshida M, et al. Human neonatal fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 2004;20:769-783.
29. Quiding-Jarbrink M, et al. Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses. J Clin Invest 1997;99:1281-1286.
30. Chang SY, et al. Cutting edge: Langerin+ dendritic cells in the mesenteric lymph node set the stage for skin and gut immune system cross-talk. J Immunol 2008;180:4361-4365.
31. el-Kamary SS, et al. Adjuvanted intranasal Norwalk VLP vaccine elicits antibodies and antibody secreting cells expressing homing receptors in mucosal and peripheral lymphoid tissues. J Infect Dis 2010; in press.
32. Kunkel EJ, Butcher EC. Plasma-cell homing. Nat Rev Immunol 2003;3:822-829.
33. Crotty S, Aubert RD, Glidewell J, Ahmed R. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods 2004;286:111-122.
34. Avery DT, Ellyard JI, Mackay F, Corcoran LM, Hodgkin PD, Tangye SG. Increased expression of CD27 on activated human memory B cells correlates with their commitment to the plasma cell lineage. J Immunol 2005;174:4034-4042.
35. Rojas OL, et al. Evaluation of circulating intestinally committed memory B cells in children vaccinated with attenuated human rotavirus vaccine. Viral Immunol 2007;20:300-311.
36. Harris AM, et al. Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. Infect Immun 2009;77:3850-3856.
37. Simon JK, et al. Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidates. Vaccine 2009;27:565-572.
38. Oswald-Richter K, et al. Identification of a CCR5-expressing T cell subset that is resistant to R5-tropic HIV infection. PLoS Pathog 2007;3:e58.
39. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004;22:745-763.
40. Lefrancois L. Development, trafficking, and function of memory T-cell subsets. Immunol Rev 2006;211:93-103.
41. Butcher EC, Williams M, Youngman K, Rott L, Briskin M. Lymphocyte trafficking and regional immunity. Adv Immunol 1999;72:209-253.
42. Salmi M, Jalkanen S. Lymphocyte homing to the gut: attraction, adhesion, and commitment. Immunol Rev 2005;206:100-113.
43. Kunkel EJ, et al. Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. J Exp Med 2000;192:761-768.
44. Cheroutre H, Madakamutil L. Acquired and natural memory T cells join forces at the mucosal front line. Nat Rev Immunol 2004;4:290-300.
45. Muller S, Buhler-Jungo M, Mueller C. Intestinal intraepithelial lymphocytes exert potent protective cytotoxic activity during an acute virus infection. J Immunol 2000;164:1986-1994.
46. Fahrer AM, Konigshofer Y, Kerr EM, et al. Attributes of gammadelta intraepithelial lymphocytes as suggested by their transcriptional profile. Proc Natl Acad Sci USA 2001;98:10261-10266.
47. Komano H, et al. Homeostatic regulation of intestinal epithelia by intraepithelial gamma delta T cells. Proc Natl Acad Sci USA 1995;92:6147-6151.
48. Hayday A, Theodoridis E, Ramsburg E, Shires J. Intraepithelial lymphocytes: exploring the Third Way in immunology. Nat Immunol 2001;2:997-1003.
49. Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 1998;279:1737-1740.
50. Saurer L, Mueller C. T cell-mediated immunoregulation in the gastrointestinal tract. Allergy 2009;64:505-519.
51. Nagler-Anderson C, Bhan AK, Podolsky DK, Terhorst C. Control freaks: immune regulatory cells. Nat Immunol 2004;5:119-122.
52. Roncarolo MG, Gregori S. Is FOXP3 a bona fide marker for human regulatory T cells? Eur J Immunol 2008;38:925-927.
53. Allez M, Brimnes J, Dotan I, Mayer L. Expansion of CD8+ T cells with regulatory function after interaction with intestinal epithelial cells. Gastroenterology 2002;123:1516-1526.
54. Grdic D, Hornquist E, Kjerrulf M, Lycke NY. Lack of local suppression in orally tolerant CD8-deficient mice reveals a critical regulatory role of CD8+ T cells in the normal gut mucosa. J Immunol 1998;160:754-762.
55. Hu D, Ikizawa K, Lu L, Sanchirico ME, Shinohara ML, Cantor H. Analysis of regulatory CD8 T cells in Qa-1-deficient mice. Nat Immunol 2004;5:516-523.
56. Chess L, Jiang H. Resurrecting CD8+ suppressor T cells. Nat Immunol 2004;5:469-471.
57. Mucida D, Salek-Ardakani S. Regulation of TH17 cells in the mucosal surfaces. J Allergy Clin Immunol 2009;123:997-1003.
58. Ivanov II, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 2008;4:337-349.
59. Ochiai RL, et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull World Health Organ 2008;86:260-268.
60. Lin FY, et al. The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam. Am J Trop Med Hyg 2000;62:644-648.
61. Sinha A, et al. Typhoid fever in children aged less than 5 years. Lancet 1999;354:734-737.
62. Brooks WA, et al. Bacteremic typhoid fever in children in an urban slum, Bangladesh. Emerg Infect Dis 2005;11:326-329.
63. Ferreccio C, et al. Benign bacteremia caused by Salmonella typhi and paratyphi in children younger than 2 years. J Pediatr 1984;104:899-901.
64. Connor BA, Schwartz E. Typhoid and paratyphoid fever in travellers. Lancet Infect Dis 2005;5:623-628.
65. Charles RC, et al. Characterization of anti-Salmonella enterica serotype Typhi antibody responses in bacteremic Bangladeshi patients using Immuno-affinity Proteomic-based Technology (IPT). Clin Vaccine Immunol 2010;17:1188-1195.
66. Ortiz V, Isibasi A, Garcia Ortigoza E, Kumate J. Immunoblot detection of class-specific humoral immune response to outer membrane proteins isolated from Salmonella typhi in humans with typhoid fever. J Clin Microbiol 1989;27:1640-1645.
67. Sheikh A, et al. Salmonella enterica serovar Typhi-specific immunoglobulin A antibody responses in plasma and antibody in lymphocyte supernatant specimens in Bangladeshi patients with suspected typhoid fever. Clin Vaccine Immunol 2009;16:1587-1594.
68. Rajagopalan P, Kumar R, Malaviya AN. Immunological studies in typhoid fever. II. Cell-mediated immune responses and lymphocyte subpopulations in patients with typhoid fever. Clin Exp Immunol 1982;47:269-274.
69. Lanata CF, et al. Vi serology in detection of chronic Salmonella typhi carriers in an endemic area. Lancet 1983;2:441-443.
70. Losonsky GA, Ferreccio C, Kotloff KL, Kaintuck S, Robbins JB, Levine MM. Development and evaluation of an enzyme-linked immunosorbent assay for serum Vi antibodies for detection of chronic Salmonella typhi carriers. J Clin Microbiol 1987;25:2266-2269.
71. Mirza NB, Wamola IA, Estambale BA, Mbithi E, Poillet M. Typhim Vi vaccine against typhoid fever: a clinical trial in Kenya. East Afr Med J 1995;72:162-164.
72. Murphy JR, et al. Immunity to Salmonella typhi: considerations relevant to measurement of cellular immunity in typhoid-endemic regions. Clin Exp Immunol 1989;75:228-233.
73. Murphy JR, et al. Characteristics of humoral and cellular immunity to Salmonella typhi in residents of typhoid-endemic and typhoid-free regions. J Infect Dis 1987;156:1005-1109.
74. Butler T, Ho M, Acharya G, Tiwari M, Gallati H. Interleukin-6, gamma interferon, and tumor necrosis factor receptors in typhoid fever related to outcome of antimicrobial therapy. Antimicrob Agents Chemother 1993;37:2418-2421.
75. Salerno-Goncalves R, Sztein MB. Priming of Salmonella enterica serovar typhi-specific CD8(+) T cells by suicide dendritic cell cross-presentation in humans. PLoS ONE 2009;4:e5879.
76. Kopecko DJ, et al. Genetic stability of vaccine strain Salmonella Typhi Ty21a over 25 years. Int J Med Microbiol 2009;299:233-246.
77. Simanjuntak C, et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 1991;338:1055-1059.
78. Black R, et al. Immunogenicity of Ty21a attenuated "Salmonella typhi" given with sodium bicarbonate or in enteric-coated capsules. Dev Biol Stand 1983;53:9-14.
79. Levine MM, Ferreccio C, Black RE, Tacket CO, Germanier R, Chilean Typhoid Committee. Progress in vaccines to prevent typhoid fever. Rev Infect Dis 1989;11:S552-S567.
80. Black RE, Levine MM, Ferreccio C, et al. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee. Vaccine 1990;8:81-84.
81. Levine MM, Ferreccio C, Cryz S, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet 1990;336:891-894.
82. Wahdan MH, Serie C, Cerisier Y, Sallam S, Germanier R. A controlled field trial of live Salmonella Typhi strain Ty 21a oral vaccine against typhoid: three-year results. J Infect Dis 1982;145:292-295.
83. Levine MM, Ferreccio C, Black RE, Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987;1:1049-1052.
84. Ferreccio C, Levine MM, Rodriguez H, Contreras R. Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. JID 1989;159:766-769.
85. Levine MM, Ferreccio C, Abrego P, Martin OS, Ortiz E, Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella Typhi live oral vaccine. Vaccine 1999;17(Suppl.):S22-S27.
86. Cryz SJ Jr, Vanprapar N, Thisyakorn U, et al. Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children. Infect Immun 1993;61:1149-1151.
87. Salerno-Goncalves R, Wahid R, Sztein MB. Ex vivo kinetics of early and long-term multifunctional HLA-E specific CD8+ cells in volunteers immunized with Ty21a typhoid vaccine. Clin Vaccine Immunol 2010;17:1305-1314.
88. Sztein MB. Cell-mediated immunity and antibody responses elicited by attenuated Salmonella enterica serovar Typhi strains used as live oral vaccines in humans. Clin Infect Dis 2007;45(Suppl.):S15-S19.
89. Salerno-Goncalves R, Fernandez-Vina M, Lewinsohn DM, Sztein MB. Identification of a human HLA-E-restricted CD8+ T cell subset in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine. J Immunol 2004;173:5852-5862.
90. + effector T cell responses in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine. J Immunol 2002;169:2196-2203.
91. + T cells with predominant Vbeta repertoires. Infect Immun 2005;73:3521-3530.
92. Kantele A. Peripheral blood antibody-secreting cells in the evaluation of the immune response to an oral vaccine. J Biotechnol 1996;44:217-224.
93. Kantele A, et al. Homing potentials of circulating lymphocytes in humans depend on the site of activation: oral, but not parenteral, typhoid vaccination induces circulating antibody-secreting cells that all bear homing receptors directing them to the gut. J Immunol 1997;158:574-579.
94. Kantele A. Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine. Vaccine 1990;8:321-326.
95. D'Amelio R, Tagliabue A, Nencioni L, et al. Comparative analysis of immunological responses to oral (Ty21a) and parenteral (TAB) typhoid vaccines. Infect Immun 1988;56:2731-2735.
96. Tagliabue A, Nencioni L, Caffarena A, et al. Cellular immunity against Salmonella typhi after live oral vaccine. Clin Exp Immunol 1985;62:242-247.
97. + T cells in humans. Infect Immun 2002;70:5622-5627.
98. + T cell responses. J Exp Med 2007;204:1405-1416.
99. Betts MR, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006;107:4781-4789.
100. + T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003;281:65-78.
101. Tacket CO, et al. Phase 2 clinical trial of attenuated Salmonella enterica serovar Typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect Immun 2000;68:1196-1201.
102. + T cell responses in volunteers immunized with Salmonella enterica serovar Typhi strain CVD 908-htrA. J Immunol 2003;170:2734-2741.
103. Levine MM, Kaper JB, Black RE, Clements ML. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev 1983;47:510-550.
104. Glass RI, Svennerholm AM, Khan MR, Huda S, Huq MI, Holmgren J. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis 1985;151:236-242.
105. Clemens JD, et al. Biotype as determinant of natural immunising effect of cholera. Lancet 1991;337:883-884.
106. Levine MM, et al. Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans R Soc Trop Med Hyg 1979;73:3-9.
107. Levine MM, Black RE, Clements ML, Cisneros L, Nalin DR, Young CR. Duration of infection-derived immunity to cholera. J Infect Dis 1981;143:818-820.
108. Kaper JB, Morris JG Jr, Levine MM. Cholera. Clin Microbiol Rev 1995;8:48-86.
109. World Health Organization. Cholera vaccines. Wkly Epidemiol Rec 2001;76:117-124.
110. Dukoral (package insert). Stockholm, Sweden: Crucell/SBL Vaccines, 2007.
111. Ryan ET, Calderwood SB. Cholera vaccines. J Travel Med 2001;8:82-91.
112. Sur D, Lopez AL, Kanungo S, et al. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1694-1702.
113. Kanungo S, Paisley A, Lopez AL, et al. Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial. Vaccine 2009;27:6887-6893.
114. Ketley JM, Michalski J, Galen J, Levine MM, Kaper JB. Construction of genetically marked Vibrio cholerae O1 vaccine strains. FEMS Microbiol Lett 1993;111:15-21.
115. Qadri F, et al. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine 2007;25:231-238.
116. Garcia L, et al. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect Immun 2005;73:3018-3024.
117. Svennerholm AM, Gothefors L, Sack DA, Bardhan PK, Holmgren J. Local and systemic antibody responses and immunological memory in humans after immunization with cholera B subunit by different routes. Bull World Health Organ 1984;62:909-918.
118. Losonsky GA, Tacket CO, Wasserman SS, Kaper JB, Levine MM. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection. Infect Immun 1993;61:729-733.
119. Qadri F, et al. Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers. Infect Immun 2003;71:4808-4814.
120. Asaduzzaman M, et al. The major subunit of the toxin-coregulated pilus TcpA induces mucosal and systemic immunoglobulin A immune responses in patients with cholera caused by Vibrio cholerae O1 and O139. Infect Immun 2004;72:4448-4454.
121. Bhuiyan TR, et al. Cholera caused by Vibrio cholerae O1 induces T-cell responses in the circulation. Infect Immun 2009;77:1888-1893.
122. Weil AA, et al. Memory T-cell responses to Vibrio cholerae O1 infection. Infect Immun 2009;77:5090-5096.
123. Kantele A, Kantele JM, Arvilommi H, Makela PH. Active immunity is seen as a reduction in the cell response to oral live vaccine. Vaccine 1991;9:428-431.
124. Kotloff KL, et al. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine 1995;13:1488-1494.
125. Sack DA, et al. Antibody responses after immunization with killed oral cholera vaccines during the 1985 vaccine field trial in Bangladesh. J Infect Dis 1991;164:407-411.
126. Iwasaki A, Welker R, Mueller S, Linehan M, Nomoto A, Wimmer E. Immunofluorescence analysis of poliovirus receptor expression in Peyer's patches of humans, primates, and CD155 transgenic mice: implications for poliovirus infection. J Infect Dis 2002;186:585-592.
127. Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis 1985;151:420-436.
128. Aylward RB. Eradicating polio: today's challenges and tomorrow's legacy. Ann Trop Med Parasitol 2006;100:401-413.
129. Strebel PM, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 1992;14:568-579.
130. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010;17:1055-1065.
131. Ogra PL, Fishaut M, Gallagher MR. Viral vaccination via the mucosal routes. Rev Infect Dis 1980;2:352-369.
132. Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J Infect Dis 1991;163:1-6.
133. Ogra PL. Comparative evaluation of immunization with live attenuated and inactivated poliovirus vaccines. Ann N Y Acad Sci 1995;754:97-107.
134. Grimwood K, Lambert SB, Milne RJ. Rotavirus infections and vaccines: burden of illness and potential impact of vaccination. Paediatr Drugs 2010;12:235-256.
135. Clark B, McKendrick M. A review of viral gastroenteritis. Curr Opin Infect Dis 2004;17:461-469.
136. Parashar UD, Alexander JP, Glass RI. Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55:1-13.
137. Wilhelmi I, Roman E, Sanchez-Fauquier A. Viruses causing gastroenteritis. Clin Microbiol Infect 2003;9:247-262.
138. Ball JM, Tian P, Zeng CQ, Morris AP, Estes MK. Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein. Science 1996;272:101-104.
139. Lorrot M, Vasseur M. Physiopathology of rotavirus diarrhea. Arch Pediatr 2007;14(Suppl.):S145-S151.
140. Murphy TV, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001;344:564-572.
141. Murphy TV, Smith PJ, Gargiullo PM, Schwartz B. The first rotavirus vaccine and intussusception: epidemiological studies and policy decisions. J Infect Dis 2003;187:1309-1313.
142. Rennels MB, Glass RI, Dennehy PH, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics 1996;97:7-13.
143. Santosham M, et al. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr 1997;131:632-638.
144. Joensuu J, Koskenniemi E, Pang XL, Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997;350:1205-1209.
145. Vesikari T, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007;370:1757-1763.
146. Cortese MM, Parashar UD. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2009;58:1-25.
147. World Health Organization. Meeting of the immunization Strategic Advisory Group of Experts, April 2009 - conclusions and recommendations. Wkly Epidemiol Rec 2009;84:220-236.
148. Velazquez FR, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996;335:1022-1028.
149. Franco MA, Angel J, Greenberg HB. Immunity and correlates of protection for rotavirus vaccines. Vaccine 2006;24:2718-2731.
150. Kapikian AZ, et al. Oral administration of human rotavirus to volunteers: induction of illness and correlates of resistance. J Infect Dis 1983;147:95-106.
151. Hjelt K, Grauballe PC, Paerregaard A, Nielsen OH, Krasilnikoff PA. Protective effect of preexisting rotavirus-specific immunoglobulin A against naturally acquired rotavirus infection in children. J Med Virol 1987;21:39-47.
152. Brown KA, Kriss JA, Moser CA, Wenner WJ, Offit PA. Circulating rotavirus-specific antibody-secreting cells (ASCs) predict the presence of rotavirus-specific ASCs in the human small intestinal lamina propria. J Infect Dis 2000;182:1039-1043.
153. Ward RL, et al. Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis 1989;159:79-88.
154. Matson DO, O'Ryan ML, Herrera I, Pickering LK, Estes MK. Fecal antibody responses to symptomatic and asymptomatic rotavirus infections. J Infect Dis 1993;167:577-583.
155. Coulson BS, Grimwood K, Hudson IL, Barnes GL, Bishop RF. Role of coproantibody in clinical protection of children during reinfection with rotavirus. J Clin Microbiol 1992;30:1678-1684.
156. Freytag LC, Clements JD. Mucosal adjuvants. Vaccine 2005;23:1804-1813.
157. Dickinson BL, Clements JD. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun 1995;63:1617-1623.
158. Freytag LC, Clements JD, Eliasson D, Lycke N. Use of genetically or chemically detoxified mutants of cholera and Escherichia coli heat-labile enterotoxins as mucosal adjuvants. In: Levine MM, Dougan G, Good MF, Liu MA, Nabel GJ, Nataro JPRR eds. New Generation Vaccines. 4th edn. New York: Informa Healthcare USA, Inc., 2010:273-283.
159. Giuliani MM, et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp Med 1998;187:1123-1132.
160. Douce G, Giuliani MM, Giannelli V, Pizza MG, Rappuoli R, Dougan G. Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli. Vaccine 1998;16:1065-1073.
161. Marchetti M, et al. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine 1998;16:33-37.
162. Anosova NG, Chabot S, Shreedhar V, Borawski JA, Dickinson BL, Neutra MR. Cholera toxin, E. coli heat-labile toxin, and non-toxic derivatives induce dendritic cell migration into the follicle-associated epithelium of Peyer's patches. Mucosal Immunol 2008;1:59-67.
163. Anjuere F, et al. In vivo adjuvant-induced mobilization and maturation of gut dendritic cells after oral administration of cholera toxin. J Immunol 2004;173:5103-5111.
164. Baqar S, et al. Standardization of measurement of immunoglobulin-secreting cells in human peripheral circulation. Clin Diagn Lab Immunol 1997;4:375-379.
165. Kotloff KL, Sztein MB, Wasserman SS, Losonsky GA, DiLorenzo SC, Walker RI. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun 2001;69:3581-3590.
166. Losonsky GA, Kotloff KL, Walker RI. B cell responses in gastric antrum and duodenum following oral inactivated Helicobacter pylori whole cell (HWC) vaccine and LT(R192G) in H. pylori seronegative individuals. Vaccine 2003;21:562-565.
167. Tribble D, et al. Modified Escherichia coli heat-labile (LT(R192G)) adjuvant dose-range study of an oral, inactivated whole cell Campylobacter (CWC) vaccine in volunteers. 1st International Conference on Modern Vaccines, Adjuvants and Delivery Systems, Dublin, Ireland, 4-6 June, 2003.
168. Lapa JA, et al. Randomized clinical trial assessing the safety and immunogenicity of oral microencapsulated enterotoxigenic Escherichia coli surface antigen 6 with or without heat-labile enterotoxin with mutation R192G. Clin Vaccine Immunol 2008;15:1222-1228.
169. Clements JD. Target tissue responses to antigens and adjuvants. 2nd International Conference on Modern Mucosal Vaccine, Adjuvants and Microbicides, Dublin, Ireland, 28-30 April, 2010.
170. Yuki Y, et al. Oral MucoRice expressing double-mutant cholera toxin A and B subunits induces toxin-specific neutralising immunity. Vaccine 2009;27:5982-5988.
171. Summerton NA, et al. Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine 2010;28:1404-1411.
172. Brandtzaeg P. Food allergy: separating the science from the mythology. Nat Rev Gastroenterol Hepatol 2010;7:380-400.
173. Levine MM. Use of vaccines for the prevention of typhoid fever. Indian Pediatr 2003;40:1029-1034.
174. Tacket CO, Levine MM. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression. Clin Infect Dis 2007;45(Suppl.):S20-S23.
175. Hindle Z, et al. Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect Immun 2002;70:3457-3467.
176. Kirkpatrick BD, Tenney KM, Larsson CJ, et al. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations. J Infect Dis 2005;192:360-366.
177. Kirkpatrick BD, et al. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine 2006;24:116-123.
178. Hohmann EL, Oletta CA, Killeen KP, Miller SI. PhoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J Infect Dis 1996;173:1408-1414.
179. Tacket CO, et al. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect Immun 1997;65:452-456.
180. Tacket CO, Pasetti MF, Sztein MB, Livio S, Levine MM. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide. J Infect Dis 2004;190:565-570.
181. Wang JY, et al. Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated δguaBA Salmonella enterica serovar Typhi strain CVD 915. Infect Immun 2001;69:4734-4741.
182. Sztein MB, et al. Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. J Infect Dis 1994;170:1508-1517.
183. Sztein MB, Tanner M, Polotsky Y, Orenstein JM, Levine MM. Cytotoxic T lymphocytes after oral immunization with attenuated vaccine strains of Salmonella typhi in humans. J Immunol 1995;155:3987-3993.
184. Wahid R, Salerno-Goncalves R, Tacket CO, Levine MM, Sztein MB. Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909. Vaccine 2007;25:1416-1425.
185. Wyant TL, Tanner MK, Sztein MB. Salmonella typhi flagella are potent inducers of proinflammatory cytokine secretion by human monocytes. Infect Immun 1999;67:3619-3624.
186. Wahid R, Salerno-Goncalves R, Tacket CO, Levine MM, Sztein MB. Generation of specific effector and memory T cells with gut- and secondary lymphoid tissue- homing potential by oral attenuated CVD 909 typhoid vaccine in humans. Mucosal Immunol 2008;1:389-398.
187. Geginat J, Lanzavecchia A, Sallusto F. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 2003;101:4260-4266.
188. Maskey AP, et al. Salmonella enterica serovar Paratyphi A and S. enterica serovar Typhi cause indistinguishable clinical syndromes in Kathmandu, Nepal. Clin Infect Dis 2006;42:1247-1253.
189. Karkey A, Aryjal A, Basnyat B, Baker S. Kathmandu, Nepal: still an enteric fever capital of the world. J Infect Dev Ctries 2008;2:461-465.
190. Ochiai RL, Wang X, von SL, et al. Salmonella paratyphi A rates, Asia. Emerg Infect Dis 2005;11:1764-1766.
191. Levine MM, Ferreccio C, Black RE, Lagos R, San MO, Blackwelder WC. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin Infect Dis 2007;45(Suppl.):S24-S28.
192. Levine MM, et al. Expanding immunization against human Salmonella infections: vaccines to prevent invasive non-typhoidal Salmonella emerging in sub-Saharan Africa and Salmonella Paratyphi in Asia. 4th Vaccine and International Society for Vaccines Annual Global Congress. Vienna, Austria. October 3-5, 2010.
193. Kotloff KL, Pasetti MF, Barry EM, et al. Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. J Infect Dis 2004;190:1745-1754.
194. Cohen D, Green MS, Block C, Slepon R, Ofek I. Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis. J Clin Microbiol 1991;29:386-389.
195. Black RE, et al. Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. J Infect Dis 1987;155:1260-1265.
196. Tacket CO, Binion SB, Bostwick E, Losonsky G, Roy MJ, Edelman R. Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge. Am J Trop Med Hyg 1992;47:276-283.
197. Clemens JD, Stanton B, Stoll B, Shahid NS, Banu H, Chowdhury AK. Breast feeding as a determinant of severity in shigellosis. Evidence for protection throughout the first three years of life in Bangladeshi children. Am J Epidemiol 1986;123:710-720.
198. Kotloff KL, et al. Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2. Vaccine 1995;13:495-502.
199. Coster TS, et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 1999;67:3437-3443.
200. Raqib R, Ljungdahl A, Lindberg AA, Andersson U, Andersson J. Local entrapment of interferon gamma in the recovery from Shigella dysenteriae type 1 infection. Gut 1996;38:328-336.
201. Raqib R, Wretlind B, Andersson J, Lindberg AA. Cytokine secretion in acute shigellosis is correlated to disease activity and directed more to stool than to plasma. J Infect Dis 1995;171:376-384.
202. Raqib R, Lindberg AA, Wretlind B, Bardhan PK, Andersson U, Andersson J. Persistence of local cytokine production in shigellosis in acute and convalescent stages. Infect Immun 1995;63:289-296.
203. Samandari T, et al. Production of IFN-gamma and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a Shiga toxin-deleted Shigella dysenteriae type 1 strain. J Immunol 2000;164:2221-2232.
204. Noriega FR, Liao FM, Maneval DR, Ren S, Formal SB, Levine MM. Strategy for cross-protection among Shigella flexneri serotypes. Infect Immun 1999;67:782-788.
205. Kotloff KL, et al. Safety and immunogenicity of CVD 1208S, a live, oral δaguaBA δsen δset Shigella flexneri 2a vaccine grown on animal-free media. Hum Vaccin 2007;3:268-275.
206. Galen JE, Pasetti MF, Tennant S, Ruiz-Olvera P, Sztein MB, Levine MM. Salmonella enterica serovar Typhi live vector vaccines finally come of age. Immunol Cell Biol 2009;87:400-412.
207. Curtiss R III, et al. New technologies in using recombinant attenuated Salmonella vaccine vectors. Crit Rev Immunol 2010;30:255-270.
208. Galen JE, et al. A new generation of stable, nonantibiotic, low-copy-number plasmids improves immune responses to foreign antigens in Salmonella enterica serovar Typhi live vectors. Infect Immun 2010;78:337-347.
209. Vindurampulle CJ, Cuberos LF, Barry EM, Pasetti MF, Levine MM. Recombinant Salmonella enterica serovar Typhi in a prime-boost strategy. Vaccine 2004;22:3744-3750.
210. Galen JE, et al. Mucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine. J Infect Dis 2009;199:326-335.
211. Ramirez K, Capozzo AV, Lloyd SA, Sztein MB, Nataro JP, Pasetti MF. Mucosally delivered Salmonella typhi expressing the Yersinia pestis F1 antigen elicits mucosal and systemic immunity early in life and primes the neonatal immune system for a vigorous anamnestic response to parenteral F1 boost. J Immunol 2009;182:1211-1222.
212. Ramirez K, Ditamo Y, Galen JE, Baillie LW, Pasetti MF. Mucosal priming of newborn mice with S. Typhi Ty21a expressing anthrax protective antigen (PA) followed by parenteral PA-boost induces B and T cell-mediated immunity that protects against infection bypassing maternal antibodies. Vaccine 2010;28:6065-6075.
213. Woodland DL. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 2004;25:98-104.
214. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol 2003;108:241-247.
215. Demberg T, Robert-Guroff M. Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int Rev Immunol 2009;28:20-48.
216. Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal Immunol 2008;1:23-30.
217. Mercier GT, et al. Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine 2007;25:8687-8701.
218. Ko SY, et al. Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors. J Virol 2009;83:748-756.
219. Lugade AA, Kalathil S, Heald JL, Thanavala Y. Transgenic plant-based oral vaccines. Immunol Invest 2010;39:468-482.
220. Tacket CO. Plant-based oral vaccines: results of human trials. Curr Top Microbiol Immunol 2009;332:103-117.
221. Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, Arntzen CJ. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med 1998;4:607-609.
222. Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis 2000;182:302-305.
223. Tacket CO, Pasetti MF, Edelman R, Howard JA, Streatfield S. Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn. Vaccine 2004;22:4385-4389.
224. Chen RT, et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990;162:1036-1042.
225. Tacket CO, et al. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination. Infect Immun 1999;67:6341-6345.
226. Losonsky GA, et al. Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera. Infect Immun 1996;64:10-15.
227. Levine MM, Nalin DR, Hoover DL, Bergquist EJ, Hornick RB, Young CR. Immunity to enterotoxigenic Escherichia coli. Infect Immun 1979;23:729-736.
228. Levine MM, Black RE, Brinton CC Jr, et al. Reactogenicity, immunogenicity and efficacy studies of Escherichia coli type 1 somatic pili parenteral vaccine in man. Scand J Infect Dis 1982;33(Suppl.):83-95.
229. Tacket CO, et al. Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med 1988;318:1240-1243.
230. Tribble DR, et al. Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans. Infect Immun 2010;78:1750-1759.
231. Mosley WH, McCormack WM, Ahmed A, Chowdhury AK, Barui RK. Report of the 1966-67 cholera vaccine field trial in rural East Pakistan. 2. Results of the serological surveys in the study population - the relationship of case rate to antibody titre and an estimate of the inapparent infection rate with Vibrio cholerae. Bull World Health Organ 1969;40:187-197.
232. Mosley WH, Woodward WE, Aziz KM, et al. The 1968-1969 cholera-vaccine field trial in rural East Pakistan. Effectiveness of monovalent Ogawa and Inaba vaccines and a purified Inaba antigen, with comparative results of serological and animal protection tests. J Infect Dis 1970;121(Suppl.):S9.
233. Mosley WH, Benenson AS, Barui R. A serological survey for cholear antibodies in rural east Pakistan. 1. The distribution of antibody in the control population of a cholera-vaccine field-trial area and the relation of antibody titre to the pattern of endemic cholera. Bull World Health Organ 1968;38:327-334.
234. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998;16:1901-1906.
235. Gaucher D, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 2008;205:3119-3131.
236. Querec TD, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009;10:116-125.
237. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010;17:840-847.
238. John TJ, Jayabal P. Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference. Am J Epidemiol 1972;96:263-269.
239. Mirzayeva R, Steele AD, Parashar UD, Zaman K, Neuzil KM, Nelson EA. Evaluation of rotavirus vaccines in Asia - are there lessons to be learnt? Vaccine 2009;27(Suppl. 5):F120-F129.
240. Hanlon P, et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1987;1:1342-1345.
241. Suharyono, Simanjuntak C, Witham N, et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet 1992;340:689-694.
242. Gotuzzo E, et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect Immun 1993;61:3994-3997.
243. Su-Arehawaratana P, et al. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J Infect Dis 1992;165:1042-1048.
244. Hallander HO, et al. Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children. Vaccine 2002;21:138-145.
245. Walker A. Breast milk as the gold standard for protective nutrients. J Pediatr 2010;156:S3-S7.
246. Lagos R, Fasano A, Wasserman SS, et al. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J Infect Dis 1999;180:1709-1712.
247. Cooper PJ, et al. Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. J Infect Dis 2000;182:1199-1206.
248. Szu SC, Robbins JB, Schneerson R, Lin FY. Polysaccharide-based conjugate vaccines for enteric bacterial infections: typhoid fever, nontyphoidal Salmonellosis, and E. coli O157:H7. In: Levine MM, et al. eds. New Generation Vaccine. 4th edn. New York: Informa Healthcare USA, 2010:489-496.